Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention-Phase I Clinical Trial to Assess the Safety.

NCT05724576 is registered in ClinicalTrials.gov with Taiwan Bio Therapeutics Inc. as lead sponsor.

NCT NCT05724576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05724576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention-Phase I Clinical Trial to Assess the Safety.
Lead sponsor
Taiwan Bio Therapeutics Inc.
Phase
Phase 1
Overall status
Terminated
Start date
June 26, 2023
Completion date
May 18, 2026
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

safety issues